At this year’s Bioprocessing Summit, Dr Graham Whyteside presented on 'Inducible synthetic promoters for the production of gene therapy viral vectors'. Synpromics has developed a novel proprietary inducible expression platform that provides exquisite and tuneable control of gene expression.
Synpromics announces that it has completed a financing round including £2.1m of new funding from Calculus Capital (“Calculus”). The funds will be used for business expansion and further development of Synpromics’ proprietary synthetic promoter technology.
Synpromics Limited, a leading synthetic biology company, is pleased to announce that it has formed a collaboration with uniQure N.V., a world leader and pioneer in human gene therapy, to develop synthetic promoters with specific application in the delivery of gene medicines to liver.
Synpromics Limited, a privately held, Scottish-based synthetic biology company today announced that it has successfully generated several highly effective synthetic promoters for use in plants.
Collaborating with a leading multinational company is an exceptional achievement for this young biotechnology company, based at Edinburgh BioQuarter.